The role of RNA alternative splicing in regulating cancer metabolism
Authors:
- 20 April 2017
- journal article
- review article
- Published by Springer Nature in Human Genetics
- Vol. 136 (9) , 1113-1127
Abstract
Tumor cells alter their metabolism by a wide array of mechanisms to promote growth and proliferation. Dysregulated expression and/or somatic mutations of key components of the glycolytic pathway/TCA cycle as well as other metabolic pathways allow tumor cells to improve their ability to survive harsh conditions such as hypoxia and the presence of reactive oxygen species, as well as the ability to obtain nutrients to increase lipids, protein, and nucleic acids biogenesis. Approximately 95% of the human protein encoding genes undergo alternative splicing (AS), a regulated process of gene expression that greatly diversifies the proteome by creating multiple proteins from a single gene. In recent years, a growing body of evidence suggests that unbalanced AS, the formation of certain pro-tumorigenic isoforms and the reduction of anti-tumorigenic isoforms, is implicated in a variety of cancers. It is becoming increasingly clear that cancer-associated AS contributes to increased growth and proliferation, partially due to effects on metabolic reprogramming. Here, we summarize the known roles of AS in regulating cancer metabolism. We present evidence supporting the idea that AS, in many types of cancer, acts as a molecular switch that alters metabolism to drive tumorigenesis. We propose that the elucidation of misregulated AS and its downstream effects on cancer metabolism emphasizes the need for new therapeutic approaches aiming to modulate the splicing machinery to selectively target cancer cells.Keywords
Funding Information
- Melanoma Research Alliance (307699)
- Israel Science Foundation (1290/12)
- Israel Cancer Research Fund (Len & Susan Mark Initiative for Ovarian and Uterine/MMMT Cancers Award)
This publication has 186 references indexed in Scilit:
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- Oncogenic Splicing Factor SRSF1 Is a Critical Transcriptional Target of MYCCell Reports, 2012
- Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1Cell, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- 2011: the immune hallmarks of cancerCancer Immunology, Immunotherapy, 2011
- Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic TransformationCancer Cell, 2010
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1Molecular Cell, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Adaptable Molecular Interactions Guide Phosphorylation of the SR Protein ASF/SF2 by SRPK1Journal of Molecular Biology, 2008
- The Hallmarks of CancerCell, 2000